AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9141524
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 3 weeks
Trial: 8246770
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g galactose + 25 g glucose
Trial: 3658567
Drug: Standard methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methylphenidate (Ritalin, 10 mg, administered twice daily)
Trial: 18345471
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of specific psychotherapies with antidepressive medication
Trial: 14524397
Drug: Nonpharmacologic methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic methods of pain relief (labor support, intradermal water blocks, warm water baths)
Trial: 25031330
Drug: Maternal urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal urinary iodine concentration (UIC) < 1.0 mg/L
Trial: 9256128
Drug: Amifostine (740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (740 or 910 mg/m2) followed by cisplatin (120 mg/m2) and vinblastine (5 mg/m2)
Trial: 9256128
Drug: Amifostine (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (340 mg/m2 4 days a week for 5 weeks, or 200 mg/m2 5 days a week for 6 weeks) before radiation therapy
Trial: 1723460
Drug: Enalapril (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20‐40 mg daily)
Trial: 7470225
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg IV)
Trial: 24354263
Drug: travoprost-timolol fixed
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: travoprost-timolol fixed combination (both groups)
Trial: 17460095
Drug: 2 MENT
RxNorm normalized name: MENT
DrugBank: Trestolone (DB05830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 MENT implants
Trial: 17460095
Drug: 600-mg testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600-mg testosterone pellets every 12 weeks
Trial: 8623729
Drug: tissue-plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tissue-plasminogen activator (t-PA) plus weight-adjusted heparin
Trial: 8623729
Drug: anisoylated plasminogen
RxNorm normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anisoylated plasminogen streptokinase activator complex (APSAC) without heparin
Trial: 8623729
Drug: low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose aspirin (81 mg)
Trial: 8623729
Drug: standard-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-dose aspirin (325 mg)
Trial: 24048581
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDT)
Trial: 18037095
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg/d for 6 weeks
Trial: 12383565
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg Hu23F2G (LeukoArrest)
Trial: 30992081
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (30 mg elemental zinc)
Trial: 28402324
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (50 μg daily during pregnancy through 6 weeks postpartum)
Trial: 25910787
Drug: Visualization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visualization of coronary artery calcification and lifestyle recommendations (subgroup with statin therapy)
Trial: 22683672
Drug: Diphtheria-tetanus-pertussis vaccine
RxNorm normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus-pertussis vaccine (DTP) administered after measles vaccine
Trial: 15342614
Drug: Quinidine (Q)
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine (Q) 0, 2.5, 10, 25, 50, or 75 mg twice daily with 30 mg Dextromethorphan (DM) for 7 days
Trial: 8042612
Drug: Placebo coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo coadministered with chemotherapy
Trial: 8042612
Drug: rhGM-CSF (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF (5.5 micrograms/kg SC) coadministered with chemotherapy
Trial: 25465680
Drug: Granisetron transdermal
RxNorm normalized name: Granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron transdermal system (GTS), one patch on days 1-4
Trial: 25465680
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral granisetron (control), intravenous on day 1 and oral on days 2-4
Trial: 25465680
Drug: Granisetron transdermal
RxNorm normalized name: Granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron transdermal system (GTS) and control
Trial: 23535223
Drug: Azelnidipine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine (16 mg/day)
Trial: 23535223
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic (trichlormethiazide 1 mg/day)
Trial: 15730349
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination
Trial: 10407842
Drug: Methadone substitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone substitution therapy
Trial: 2344089
Drug: 1% povidone‐iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% povidone‐iodine solution (PI)
Trial: 7027925
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of trimethoprim (TMP) per day for 14 days
Trial: 7027925
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g of sulfisoxazole (SZ) per day for 14 days
Trial: 7027925
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of trimethoprim (TMP) per day for 10 days
Trial: 16388213
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.1% bupivacaine 10 ml/hour
Trial: 16388213
Drug: Intermittent injection
RxNorm normalized name: Jelco Intermittent Injection Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent injection of 0.1% bupivacaine 10 ml hourly
Trial: 24328607
Drug: Er,Cr:YSGG laser-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser-assisted treatment with radial firing tips (RFT2 and RFT3)
Trial: 22909165
Drug: 20, 40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20, 40, 80, or 120 μg of total grass pollen recombinant protein
Trial: 16275822
Drug: High-dose oxcarbazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxcarbazepine (60 mg/kg/day)
Trial: 2265051
Drug: suxamethonium 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 2 mg kg‐1 in children
Trial: 2265051
Drug: suxamethonium 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 2 mg kg‐1 in infants
Trial: 2265051
Drug: suxamethonium 3-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 3-4 mg kg‐1 in infants
Trial: 31795546
Drug: D-galactose aging
RxNorm normalized name: D(+)-Galactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-galactose aging model group, subcutaneous injection of D-galactose (500 mg/kg) daily for 6 weeks
Trial: 31795546
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank control group, no treatment performed
Trial: 22801471
Drug: Sensory cueing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensory cueing, non‐activated wristwatch device and 5 hours of conventional therapy per week (treatment A)
Trial: 22801471
Drug: Activated wristwatch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated wristwatch prompting predetermined exercises on the hemiplegic arm for 6 hours daily, 5 days per week for three weeks (treatment B)
Trial: 18095278
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin administered at 22:00 h
Trial: 1355640
Drug: Inhaled beta‐2‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta‐2‐agonist (salbutamol 0.2 mg) plus placebo three times a day (BA+PL)
Trial: 27414470
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioral therapy (TF-CBT) delivered by lay counselors
Trial: 26331348
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 mg/kg subcutaneously) in combination with G-CSF (5 mg/kg/day increasing to 10 mg/kg/day)
Trial: 26331348
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 mg/kg)
Trial: 19597422
Drug: Plerixafor and
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor and G-CSF
Trial: 19380134
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) abciximab administration
Trial: 20817283
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous (IV) abciximab administration
Trial: 19363853
Drug: NB‐UVB +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB + LCD therapy
Trial: 15238567
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (16 mg once daily)
Trial: 8023667
Drug: Preoperative infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative infiltration of the surgical area with bupivacaine 0.25%, 40 ml (group I)
Trial: 2641954
Drug: 0.2% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NaF solution
Trial: 31486196
Drug: Plantain syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantain syrup and placebo capsule
Trial: 31486196
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid capsule and placebo syrup
Trial: 28483402
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily for 7 days, 200 mg on the first day)
Trial: 26272281
Drug: S0597 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S0597 at 200 μg/d
Trial: 26272281
Drug: S0597 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S0597 at 400 μg/d
Trial: 16434506
Drug: SRL‐ST (Sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL‐ST (Sirolimus therapy after CsA withdrawal)
Trial: 2073671
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg nightly (n = 17)
Trial: 2073671
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily (n = 8)
Trial: 2073671
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg nightly (n = 23)
Trial: 2073671
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg b.i.d. (n = 19)
Trial: 6333649
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone sodium succinate (30 mg/kg q6h X2, then 250 mg q6h X6, then tapering over 8 days)
Trial: 6333649
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methylprednisolone (1.5 mg/kg q6h X2, then 25 mg q6h X6, then tapering over 8 days)
Trial: 6333649
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone sodium succinate
Trial: 6333649
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methylprednisolone and placebo
Trial: 28840969
Drug: Intraprostatic botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic botulinum toxin type A injection (200-300 UI in 6-8 mL saline)
Trial: 17644330
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and tamoxifen 30 mg/day for one year (RT+tam)
Trial: 16096179
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% applied twice daily (BID)
Trial: 1387246
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg
Trial: 20655106
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (5 parts per million)
Trial: 30518130
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement (0.4 g protein/kg/day)
Trial: 11998383
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with perfluothane (Control)
Trial: 7985708
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber (20 g/day) administered twice a day for 36 weeks
Trial: 30106535
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg codeine + 500 mg paracetamol (CP)
Trial: 30106535
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen (IB)
Trial: 30106535
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg placebo (PL)
Trial: 27799178
Drug: Dexamethasone 2
RxNorm normalized name: dexamethasone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2 mg perineurally with ropivacaine 0.5%
Trial: 8640993
Drug: Sequential grafts
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential grafts
Trial: 2890501
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus glyburide (IG)
Trial: 11274902
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus placebo (IP)
Trial: 31412032
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia
Trial: 26509769
Drug: Carbomer-based lipid-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbomer-based lipid-containing artificial tear formulations (CBLAT) in the switching group
Trial: 26509769
Drug: Carbomer-based lipid-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbomer-based lipid-containing artificial tear formulations (CBLAT) in the add-on group
Trial: 15310534
Drug: Combination hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination hormone therapy (conjugated equine estrogen, 0.625 mg, and medroxyprogesterone, 2.5 mg)
Trial: 1864667
Drug: K-strophanthidin (0.008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-strophanthidin (0.008 mg/kg for 5-10 min)
Trial: 31833801
Drug: Originator insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator insulin aspart (NN-Asp)
Trial: 27684440
Drug: ADT +
RxNorm normalized name: Antidepressant+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT + metformin
Trial: 18761778
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (2.2 g total fatty acids/d)
Trial: 18761778
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil (2.2 g total fatty acids/d)
Trial: 31465585
Drug: Dimethylfumarate (DMF)
RxNorm normalized name: dimethylcarbate
DrugBank: Dimethyl carbate (DB13204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylfumarate (DMF) 720 mg daily
Trial: 26334856
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of methylprednisolone intravenously before CPB
Trial: 26334856
Drug: Standard CABG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CABG surgery without any additional medication (Control)
Trial: 19225268
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg/day) for 2 months
Trial: 17414740
Drug: Amisulpride (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (200-800 mg/day)
Trial: 11232746
Drug: Haloperidol (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5-20 mg/day)
Trial: 8409060
Drug: Albunex 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex 0.08 ml/kg
Trial: 8409060
Drug: Albunex 0.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex 0.22 ml/kg
Trial: 26522081
Drug: High-Ca group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Ca group (same milk powder additionally fortified with 600 mg of Ca)
Trial: 20159379
Drug: Ultrarapid IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrarapid IV hydration (50 mL/kg normal saline for 1 hour)
Trial: 20159379
Drug: Standard IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IV hydration (50 mL/kg normal saline for 3 hours)
Trial: 17654232
Drug: Antioxidant-supplemented group
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant-supplemented group (500 mg/day of vitamin E, 30 mg/day of beta-carotene, and for the last 15 days, 1 g/day of vitamin C)
Trial: 10412891
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg E2 plus 0.15 mg DSG tablets
Trial: 7751882
Drug: Eight-drugs-in-1-day chemotherapy
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight-drugs-in-1-day chemotherapy without RT
Trial: 7751882
Drug: Craniospinal RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniospinal RT and chemotherapy (vincristine, lomustine (CCNU), and prednisone)
Trial: 85937
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid 250 mg/day
Trial: 388396
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg b.d.
Trial: 388396
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tienilic acid 250 mg/day and propranolol 80 mg b.d.
Trial: 30635070
Drug: Historic control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historic control group (postoperative adjuvant chemotherapy)
Trial: 17389757
Drug: Peptide inhalation
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide inhalation
Trial: 11487742
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (345 mg/d)
Trial: 9726699
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 5 days
Trial: 30260776
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of sequential therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d)
Trial: 30260776
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Trial: 15721471
Drug: Head cooling
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34‐35 degrees C (n=116)
Trial: 12869909
Drug: Clindamycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (10 days therapy)
Trial: 2050231
Drug: Topical 13‐cis‐retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 13‐cis‐retinoic acid
Trial: 28544581
Drug: Reference medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference medication (60 mg)